Core Insights - BioHarvest Sciences reported a robust 41% year-over-year revenue growth for Q2 2025, reaching $8.5 million, driven by strong sales in its core VINIA® capsule business and new product launches [4][6] - The company aims to achieve adjusted EBITDA breakeven by Q4 2025, supported by continued growth in its product lines and a strong CDMO pipeline [3][4] Financial Performance - Total revenues for Q2 2025 increased to $8.5 million from $6.0 million in Q2 2024, with gross margins expanding by 800 basis points to 60% [4][6] - Gross profit rose 65% to $5.1 million, attributed to increased manufacturing scale and improved yields [7] - Operating expenses increased to $6.9 million from $4.8 million year-over-year, primarily due to higher marketing spend and costs associated with the CDMO services division [8] Net Loss and Cash Position - The net loss for Q2 2025 was $4.0 million, or $0.24 per share, compared to a net loss of $0.7 million, or $0.04 per share, in Q2 2024 [9] - Cash and cash equivalents as of June 30, 2025, totaled $3.7 million, up from $2.4 million at the end of 2024 [10] Product and Market Developments - The company has launched new products, including VINIA® Daily Chews 2X Formula, and secured a new CDMO contract for developing a plant-based fragrance compound [4][13] - Management expects to launch additional products and CDMO services in the second half of 2025, including an electrolyte drink targeting the $13 billion hydration market [4][13] Strategic Initiatives - BioHarvest is focusing on three growth initiatives: expanding its Health Pros affiliate program, launching a new electrolyte drink, and introducing an AI-enabled CDMO discovery phase [13] - The company continues to position its botanical synthesis technology as a commercial engine for high-value plant-based compounds [5]

Core Viewpoint - BioHarvest Sciences Inc. is set to release its financial results for the second quarter of 2025 on August 11, 2025, before market opening, and will host an investor conference call to discuss these results and provide a corporate update [1][2]. Company Overview - BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology platform to cultivate plant-based compounds without the need for the actual plants [4]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) for clients seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4]. Conference Call Details - The investor conference call will take place on August 11, 2025, at 8:00 a.m. Eastern Time, with dial-in options provided for U.S./Canada and international participants [2]. - A playback of the call will be available until August 25, 2025, with specific numbers provided for accessing the playback [3].

Core Insights - BioHarvest Sciences Inc. has been invited to present at the Canaccord Genuity 45th Annual Growth Conference scheduled for August 12-14, 2025, in Boston, Massachusetts [1] - CEO Ilan Sobel will conduct one-on-one meetings with institutional investors and will present the company's growth plans during the conference [2][3] - The company is focused on building momentum in both its consumer and contract development and manufacturing organization (CDMO) businesses, aiming to scale operations effectively [3] Company Overview - BioHarvest Sciences Inc. specializes in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need for growing the actual plants [4] - The company operates in two main business verticals: as a CDMO for clients seeking novel plant-based compounds and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements [4]

Core Viewpoint - BioHarvest Sciences Inc. has launched VINIA® DailyChews 2X Formula, a chewable product designed to enhance nitric oxide production and improve blood flow for athletes and active individuals, now available for purchase online [1][3]. Product Details - VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12mg of Piceid resveratrol, which is clinically shown to increase arterial dilation, thereby improving physical energy and mental alertness [3]. - The product is Informed Sport-certified, ensuring that every batch is tested for banned substances, making it suitable for professional athletes and fitness enthusiasts [2][3]. Market Strategy - The launch targets the multi-billion-dollar nutraceuticals market, aiming to attract a younger consumer base and expand into the athlete and fitness enthusiast segment [3]. - BioHarvest is enhancing its international e-commerce platform to facilitate global orders, allowing customers in countries like the UK and Australia to receive products directly [3]. Company Background - BioHarvest Sciences Inc. specializes in Botanical Synthesis technology, enabling the growth of plant-based compounds without the need for the actual plants [8]. - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [8].

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Core Insights - BioHarvest Sciences reported a 47% increase in first-quarter revenues, reaching $7.9 million, surpassing management's guidance [3][8][11] - The growth was primarily driven by the VINIA® business, which achieved over 50,000 active subscribers by February 2025 [3][5] - The company is expanding its product offerings and marketing strategies to target younger consumer segments [4][7] Financial Performance - Total revenues for Q1 2025 increased to $7.9 million from $5.3 million in Q1 2024, marking a 47% year-over-year growth [8] - Gross profit rose by 53% to $4.6 million, with gross margins improving to 58.5% from 56.2% [9][22] - Operating expenses increased to $6.3 million, primarily due to higher marketing expenditures, but as a percentage of revenue, it decreased to 46.8% from 48.0% [10][22] Loss and Financing - The net loss for Q1 2025 was $2.3 million, a significant reduction from a net loss of $6.6 million in the same quarter of the previous year [11][22] - The company raised $3.9 million in debt financing during the quarter, increasing cash and cash equivalents to $3.4 million [12][24] Operational Highlights - The company is advancing its CDMO division, with successful validation of its botanical synthesis platform for various molecule types [5][6] - New product lines under the VINIA® brand are being introduced, including VINIA® SuperFood Tea and VINIA® Espresso, aimed at capturing a younger demographic [4][7] - The company anticipates continued growth in both its product and service units, with expectations of reaching adjusted EBITDA breakeven in the second half of 2025 [5][7]

Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]